Mammary Cell News 11.06 February 21, 2019 | |
| |
TOP STORYTumor resection had a major impact on reducing clonal diversity in secondary sites, indicating that most disseminated tumor cells lacked the capacity to ‘seed’, and hence originated from ‘shedders’ that did not persist. [Nat Commun] Full Article | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)SLLN-15 induced a dose-dependent anti-proliferative activity in the triple-negative breast cancer cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux. [Autophagy] Abstract Using LIN28B-expressing cancer cell lines, researchers found that the rate of extracellular acidification, glucose uptake, and lactate secretion were all suppressed by LIN28B knockdown in vitro and in vivo. [Oncogene] Abstract Scientists report that FGF13-AS1 expression was decreased in breast cancer tissue compared with corresponding normal tissue, and the downregulation of FGF13-AS1 was associated with poor prognosis. [Cancer Lett] Abstract Investigators showed that TNBC cells exposed to MEK1/2-JAK2 inhibitors exhibited resistant colonies in anchorage-independent growth assays. Moreover, cells treated with various small molecule inhibitors including JAK2 promoted PDGFRβ upregulation. [J Exp Clin Cancer Res] Full Article Metastatic lung-infiltrating CD11b+Gr-1+ myeloid-derived suppressor cells induced angiogenesis in the lungs and facilitated cancer extravasation and survival that ultimately promoted lung metastases. [Breast Cancer Res] Full Article The authors examined MEDI3039, a highly potent multivalent death receptor 5 agonist, in breast cancer cell lines and in vivo models. MEDI3039 killed multiple breast cancer cell lines, but the sensitivity varied among different subtypes. [Breast Cancer Res] Full Article MicroRNA-196a Is Regulated by ER and Is a Prognostic Biomarker in ER+ Breast Cancer Scientists demonstrated that MIR196A displayed complex and dynamic expression patterns, in part controlled by long-range transcriptional regulation between promoter and enhancer elements bound by ERα. [Br J Cancer] Full Article Gain- and loss-of-function assays in vitro and in vivo revealed that sphingomyelin synthase 2 promoted cancer cell proliferation by suppressing apoptosis through a ceramide-associated pathway and promoted cancer cell invasiveness by enhancing epithelial-to-mesenchymal transition initiation through the TGF-β/Smad signaling pathway. [Cell Death Dis] Full Article Researchers found that zinc finger protein 57 (ZFP57) had low expression in breast cancer, and overexpression of ZFP57 could inhibit the proliferation of breast cancer cells by inhibiting the Wnt/β-catenin pathway. [Cell Death Dis] Full Article Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells Breast cancer cell apoptosis was observed after the addition of cell-free supernatants containing mediators released from FcεRI-challenged adipose-derived mast cells. [Front Immunol] Full Article Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSEmerging Role of Histone Deacetylase Inhibitors as Anti-Breast-Cancer Agents Preclinical and clinical data show that histone deacetylase inhibitors can evoke different anticancer mechanisms in distinct breast cancer types. [Drug Discov Today] Abstract Sequencing of Anthracyclines and Taxanes in Neoadjuvant and Adjuvant Therapy for Early Breast Cancer The authors assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breast cancer receiving adjuvant or neoadjuvant therapy. [Cochrane Database Syst Rev] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSBriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences The poster will highlight findings related to the mechanism of action of the company’s lead candidate, Bria-IMT™, to BriaDX™, the companion diagnostic test aimed at helping identify those patients most likely to benefit from Bria-IMT™, and to Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy. [Press release from BriaCell Therapeutics Corp. discussing research to be presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco] Press Release | |
| |
INDUSTRY NEWSFive Prime Therapeutics Doses First Patient in Phase Ib Trial of FPA150 Five Prime Therapeutics, Inc. announced that it initiated patient dosing in the Phase Ib dose expansion portion of the Phase Ia/Ib clinical trial of FPA150, a first-in-class immuno-oncology antibody that targets B7-H4. [Five Prime Therapeutics, Inc.] Press Release CytoDyn Inc. announced that it was able to reduce by more than 98% the incidence of human breast cancer metastasis in a mouse xenograft model for cancer through six weeks with leronlimab. Based on these results, CytoDyn announced its plans for the expansion of pre-clinical animal studies into eight cancer indications. [CytoDyn Inc.] Press Release New Early Breast Cancer Drug to Be Made Available in Singapore via Special Access Program A new breast cancer drug shown to significantly reduce the risk of cancer recurrence is being made available to women in Singapore via a Special Access Program. The drug, NERLYNX, is an oral medication taken by women with HER2+ breast cancer who have completed adjuvant trastuzumab-based therapy. [Specialised Therapeutics Asia Pte Ltd] Press Release Pfizer Receives European Approval for Zirabevâ„¢ (Bevacizumab), a Biosimilar to Avastin® Pfizer Inc. announced the European Commission has approved ZIRABEVâ„¢ for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer, advanced and/or metastatic renal cell cancer and persistent, recurrent or metastatic carcinoma of the cervix. [Pfizer Inc.] Press Release Researcher Earns Federal Grant to Study Molecule’s Potential as Cancer Drug Target Ralf Janknecht, PhD, a researcher in the Department of Cell Biology at the University of Oklahoma College of Medicine, has been analyzing the behavior of a particular molecule that is over produced in breast cancer. This year, he was awarded a five-year, $1.78 million grant from the National Cancer Institute to further evaluate the molecule’s potential in reducing cancer metastasis. [OU College of Medicine (EurekAlert!)] Press Release | |
| |
POLICY NEWSFacebook’s Controversies Now Extend to Health and Medicine Issues The Facebook controversies have come to the world of health and medicine. After last year’s scandals involving Cambridge Analytica and Russian trolls, this time the controversies concern anti-vaccine information and health privacy. [STAT News] Editorial Nearly Half of US Female Scientists Leave Full-Time Science After First Child More than 40% of women with full-time jobs in science leave the sector or go part time after having their first child, according to a study of how parenthood affects career trajectories in the United States. By contrast, only 23% of new fathers leave or cut their working hours. [Nature News] Editorial
| |
EVENTSNEW Keystone Symposia: Cancer Stem Cells – Advances in Biology and Clinical Translation Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Higher Scientific Officer – Breast Cancer Organoids (Institute of Cancer Research) Scientific Review Officer – Breast Cancer (METAvivor) Faculty Position – Breast Cancer Research (The Mayo Clinic) Postdoctoral Fellow – Cancer Bioinformatics (BC Cancer Research Center, PHSA) Postdoctoral Fellowship – Breast Cancer (Providence John Wayne Cancer Institute) International Scientific Director – Breast Cancer (Roche) Postdoctoral Researcher – Breast Cancer (The Royal College of Surgeons in Ireland) Research Fellowship – Cancer Biology (University of Dundee) Postdoctoral Fellowship – Breast Cancer (Cold Spring Harbor Laboratory) Postdoctoral Fellowship – Cancer Research (North Carolina Central University) Postdoctoral Fellow – Breast Cancer Research (City of Hope) Faculty Position – Molecular Cancer Biology (University of Pittsburgh) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|